Madeleine Hinwood
@maddiehinwood.bsky.social
Epidemiologist and statistician at Hunter Medical Research Institute
Reposted by Madeleine Hinwood
🎉 Just 2+ weeks until #AEA2025 in Nipaluna/Hobart!
What's got you most excited?
- The research presentations
- Meeting fellow epidemiologists
- Learning new methods
- Exploring Tasmania?
Drop a comment and let us know!
Still time to register if you haven't yet!
What's got you most excited?
- The research presentations
- Meeting fellow epidemiologists
- Learning new methods
- Exploring Tasmania?
Drop a comment and let us know!
Still time to register if you haven't yet!
June 30, 2025 at 4:57 AM
🎉 Just 2+ weeks until #AEA2025 in Nipaluna/Hobart!
What's got you most excited?
- The research presentations
- Meeting fellow epidemiologists
- Learning new methods
- Exploring Tasmania?
Drop a comment and let us know!
Still time to register if you haven't yet!
What's got you most excited?
- The research presentations
- Meeting fellow epidemiologists
- Learning new methods
- Exploring Tasmania?
Drop a comment and let us know!
Still time to register if you haven't yet!
Reposted by Madeleine Hinwood
Science is under siege. Political forces are undermining expertise, dismantling research institutions, and replacing evidence based policymaking with ideology.
This is a global crisis.
🧵
1/31
This is a global crisis.
🧵
1/31
March 31, 2025 at 11:31 AM
Science is under siege. Political forces are undermining expertise, dismantling research institutions, and replacing evidence based policymaking with ideology.
This is a global crisis.
🧵
1/31
This is a global crisis.
🧵
1/31
Reposted by Madeleine Hinwood
⚡️ 5 DAYS LEFT to submit your abstract for #AEA2025!
Abstract submission closes on Monday 17 February 2025, at 11:59pm AEDT
Working on something cool in epi? We want to see it in Hobart!
Still writing? You've got this! 💪 aea2025.com
Abstract submission closes on Monday 17 February 2025, at 11:59pm AEDT
Working on something cool in epi? We want to see it in Hobart!
Still writing? You've got this! 💪 aea2025.com
HOME | AEA2025
aea2025.com
February 12, 2025 at 10:54 AM
⚡️ 5 DAYS LEFT to submit your abstract for #AEA2025!
Abstract submission closes on Monday 17 February 2025, at 11:59pm AEDT
Working on something cool in epi? We want to see it in Hobart!
Still writing? You've got this! 💪 aea2025.com
Abstract submission closes on Monday 17 February 2025, at 11:59pm AEDT
Working on something cool in epi? We want to see it in Hobart!
Still writing? You've got this! 💪 aea2025.com
Looking forward to attending the AEA Scientific Meeting this year! Abstracts due 17th February: aea2025.com
Abstract deadline approaching! Don't forget to submit your work to the AEA 2025 Scientific Meeting- we are looking forward to seeing you in Hobart this July (16-18)!
aea2025.com
- Abstract submissions close Feb 17
- ECR workshop EOIs also close Feb 17
#Epidemiology
#AEA2025
#PublicHealth
aea2025.com
- Abstract submissions close Feb 17
- ECR workshop EOIs also close Feb 17
#Epidemiology
#AEA2025
#PublicHealth
HOME | AEA2025
aea2025.com
January 20, 2025 at 10:40 PM
Looking forward to attending the AEA Scientific Meeting this year! Abstracts due 17th February: aea2025.com
New preprint here: papers.ssrn.com/sol3/papers....
Results from animal studies suggest a possible safety signal associated with the use of a class of antiplatelets in certain populations; we used the target trial framework to see if we could see this signal at a population level.
Results from animal studies suggest a possible safety signal associated with the use of a class of antiplatelets in certain populations; we used the target trial framework to see if we could see this signal at a population level.
Do P2y12-Receptor Inhibitors Increase the Risk of Dementia after a Stroke? A Target Trial Emulation Using National Registry Data
Background: Recent animal studies suggest that P2Y12 receptor (P2Y12R) inhibitors, commonly prescribed after stroke for the secondary prevention of cardiovascul
papers.ssrn.com
December 17, 2024 at 10:30 PM
New preprint here: papers.ssrn.com/sol3/papers....
Results from animal studies suggest a possible safety signal associated with the use of a class of antiplatelets in certain populations; we used the target trial framework to see if we could see this signal at a population level.
Results from animal studies suggest a possible safety signal associated with the use of a class of antiplatelets in certain populations; we used the target trial framework to see if we could see this signal at a population level.